期刊文献+

抗B型肉毒毒素治疗性胞内抗体的制备及活性研究

Preparation and Study on the Activity of Anti B Botulinum Toxin in the Treatment of Cytoplasmic Antibody
下载PDF
导出
摘要 以克隆表达的B型肉毒毒素轻链蛋白(Bo NT/BL)为抗原,从噬菌体抗体库Tomlinson I+J筛选出得到活性高和特异性高的全人源单链抗体(Sc Fv),结合能够携带外源蛋白有效通过生物膜的小片段跨膜肽(TAT)制备跨膜单链抗体(TAT-Sc Fv)。经PCR后酶切,克隆到原核表达载体(p ET-28a-TAT)中,构建含有跨膜肽(TAT)的抗B型肉毒毒素胞内抗体融合蛋白,并在大肠杆菌中诱导表达,进行纯化工艺,对产物进行浓度纯度、亲和常数测定及生物活性研究。成功构建TAT-Sc Fv表达载体,融合蛋白相对分子量为32.7 k Da,主要以可溶形式表达,纯度也达到95%以上,胞内抗体中和B型肉毒毒素致病轻链得到TAT-Sc Fv的亲和常数为(1.133±0.273)×106L/mol,小鼠神经细胞乙酰胆碱定量测定实验证明胞内抗体具有较好的抗毒素活性。此结果为B型肉毒毒素治疗性胞内抗体的研制和肉毒中毒治疗奠定了基础。 Cloning and expression of botulinum toxin type B light chain protein( BoNT / BL) as antigen,the whole human single chain antibody( Sc Fv) with high activity and high specificity was obtained from phage antibody library I + J Tomlinson,Cross membrane peptide( TAT) preparation of transmembrane single chain antibodies( TAT-Sc Fv) by binding to a small fragment of a biological membrane capable of carrying a foreign protein by PCR,Connection with carrier( pET-28a-PTD),Construction of anti B type botulinum toxin recombinant antibody protein containing transmembrane peptide( TAT),And the expression was induced in E. coli. The purification process was carried out,and the concentration and purity of the product,the affinity constant and the search of biological activity. The TAT-Sc Fv expression vector was successfully constructed,and the relative molecular weight of the fusion protein was 32. 7 k Da,which was mainly expressed in soluble form,and the purity reached more than95%. Intracellular neutralizing antibodies against type B botulinum toxin light chain TAT-Sc Fv affinity constants for 1. 133 + 0. 273 × 10^6 L / mol. The mouse neuronal acetylcholine quantitative determination experiments show that intracellular antibody has better anti toxin activity,which will lay a solid foundation for the type B botulinum toxin in the treatment of intracellular antibody development and treatment of botulism.
出处 《中国兽药杂志》 北大核心 2016年第7期1-6,共6页 Chinese Journal of Veterinary Drug
基金 吉林省科技发展计划资助(20130206012yy)
关键词 跨膜肽(TAT) 重组蛋白 表达 蛋白纯化 亲和常数 乙酰胆碱 transmembrane peptide(TAT) Escherichia coli expression protein purification activity assay acetylcholine
  • 相关文献

参考文献13

  • 1Hill K K, Smith T J, Helma C H, et al. Genetic diversity among Botulinum Neurotoxin producing clostridial strains [ J ]. Journal of bacteriology ,2007,189 (3) : 818 - 832. 被引量:1
  • 2Comella C L, Pullman S L. Botnlinum toxins in neurological dis- ease [ J ]. Muscle Nerve, 2004, 29:628 - 644. 被引量:1
  • 3Melling J, Hambleton P, Shone C C. Clostridium botulinum tox- ins: nature and preparation for elinical use [ J ]. Eye, 1988,2 (Pt1) :16 -23. 被引量:1
  • 4Umeda K, Seto Y, Kohda T, et al. Genetic characterization of Clostridium botulinum associa - ted with type B infant botulism in Japan [ J ]. Journal of clinical microbiology, 2009,47 ( 9 ) : 2720 - 2728. 被引量:1
  • 5Montecucco C, Schiavo G. Mechanism of action of tetanus and botulinum neurotoxin[ J]. Mol mi - crobial, 1994,13 ( 1 ) : 1 - 8. 被引量:1
  • 6Blaustein, R. O. The N - terminal half of the heavy chain of botu- linum type A neu - rotoxin forms channels in planar phospholipid bilayers [ J ]. FEBS Lett, 1987,226 : 115 - 120. 被引量:1
  • 7Arunagiri G, Santhi S. Migraine : an ophthalmologist' s perspective [ J]. Curr Opin Ophthalmol,2003,14:344 - 352. 被引量:1
  • 8Schiavo G, Matteoli M, Montecncco C. NeurotoxJns affectingneuro- exoeytosis [ J ]. physiolRev, 2000,80 ( 2 ) : 717. 被引量:1
  • 9Simpson L. Peripheral actions of the botulinum toxins. In : Simpson L, ed. Botulinum neu -rotoxin and tetanus toxin [ M]. New York: Academic Press, 1989. 被引量:1
  • 10Bajjalieh ,S M. Synaptic vesicle docking and fusion[ J]. Curr Opin Neurobiol, 1999,9:321 - 328. 被引量:1

二级参考文献27

  • 1Shimizu YK, Weiner AJ, Rosenblatt J,et al. Early events in hepatitis C virus infection of chimpanees. Proc Vatl Acad Sci USA, 1990,87:6441-6444. 被引量:1
  • 2Hiffeuhaus J, Krupka JU, Nawak T, et al. Follow up of hepatitis C virus infection in chimpanzee determination of viraemia and specific humoral immune response. J Cen Virol, 1992,73:1015-1019. 被引量:1
  • 3Simpson L L. The origin, structure, and pharmacological activity of botulinum toxin[J]. Pharmacol Rev, 1981,33(3): 155-188. 被引量:1
  • 4Montecucco C, Schiavo G, Tugnoli V, et al. Botulinum neurotoxins: mechanism of action and therapeutic applications[J]. Mol Med Today, 1996,2(10):418-424. 被引量:1
  • 5Gill D M. Bacterial toxins: a table of lethal amounts[J]. Microbiol Rev, 1982,46(1):86-94. 被引量:1
  • 6Arnon S S, Schechter R, lnglesby T V, et al. Botulinum toxin as a biological weapon: medical and public health management[J]. JAMA, 2001,285(8):1059-1070. 被引量:1
  • 7Byrne M P, Smith L A. Development of vaccines for prevention of botulism[J]. Biochimie, 2000,82(9-10):955-966. 被引量:1
  • 8Amersdorfer P, Wong C, Chen S, et al. Molecular characterization of routine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries[J]. Infect lmmun, 1997,65(9):3743-3752. 被引量:1
  • 9DasGupta B R. Botulinum and Tetanus Neurotoxins: Neurotransmission and Biomedical Aspects[M]. New York: Plenum,1993:473-476. 被引量:1
  • 10Pless D D, Tortes E R, Reinke E K, et al. High-affinity, protective antibodies to the binding domain of botulinum neurotoxin type A[J]. Infect lmmun, 2001,69:570-574. 被引量:1

共引文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部